PF-Atlas › Клинические испытания › NCT04553419
Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF
Cephalexin · Фаза 3
ID реестра
NCT04553419
Фаза
Фаза 3
Статус
Неизвестно
Препарат / вмешательство
Cephalexin
Спонсор
University of British Columbia
Начало
2020-07-27
Набор участников
86
Центры
2
Об исследовании
This is a randomized, double-blinded study that aims to assess the effect of an oral antibiotic called Cephalexin (150 mg/kg/day) compared to placebo in clinically stable children with cystic fibrosis who have grown a bacteria called MSSA (methicillin-susceptible Staphylococcus aureus) over the course of 2 weeks. A sensitive technique called MBW (multiple breath washout) will be used to look at how well the participants lungs are functioning during the study and to see if the antibiotic improves function. The primary outcome of the study will be the relative change in the MBW measurement (LCI2.5) between day 0 and day 14 of study treatment.
Связанные материалы
Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT04553419 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.